In race to defeat fatty liver disease, Peninsula biotech lines up next clinical trial

In the race to find a drug for the fatty liver disease NASH, George Kemble isn ’t dissuaded by Sagimet Biosciences’ size; it’s the data that count. And after pivots by the San Mateo company that Kemble heads, it has promising early data back from a mid-stage study of its drug targeting nonalcoholic steatohepatitis, or NASH, and plans to take the drug into another mid-st age study early next year. The Phase II study results come as larger companies have released promising data of their own.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news